Corrigendum to “Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab” [Lung Cancer 115 (2018) 71–74](S0169500217305883)(10.1016/j.lungcan.2017.11.019);Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab

Lung Cancer

Volumn 115, Issue , 2018, Pages 71-74

  Sato, Koichi ^a   Akamatsu, Hiroaki ^a   Murakami, Eriko ^a   Sasaki, Seigo ^a   Kanai, Kuninobu ^a   Hayata, Atsushi ^a   Tokudome, Nahomi ^a   Akamatsu, Keiichiro ^a   Koh, Yasuhiro ^a   Ueda, Hiroki ^a   Nakanishi, Masanori ^a   Yamamoto, Nobuyuki ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Immune related adverse events (irAEs); Nivolumab; Non small cell lung cancer (NSCLC)

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NIVOLUMAB; STEROID; THYROTROPIN; ANTINEOPLASTIC AGENT;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FEMALE; HAZARD RATIO; HORMONE SUBSTITUTION; HUMAN; HYPERTHYROIDISM; HYPOPITUITARISM; HYPOTHYROIDISM; IMMUNOTHERAPY; INTERSTITIAL PNEUMONIA; LIVER DYSFUNCTION; MALE; NON SMALL CELL LUNG CANCER; OBSERVATIONAL STUDY; PATIENT MONITORING; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RASH; SQUAMOUS CELL LUNG CARCINOMA; TACHYCARDIA; THYROTROPIN BLOOD LEVEL; TREATMENT RESPONSE; VERY ELDERLY; ADVERSE DRUG REACTION; IMMUNOLOGY; INTERSTITIAL LUNG DISEASE; LUNG TUMOR; MIDDLE AGED; MORTALITY; PROCEDURES; SURVIVAL ANALYSIS;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; IMMUNOTHERAPY; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; NIVOLUMAB; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 85034810689     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2018.11.007     Document Type: Erratum

References (8)

1. Borghaei, H., Paz-Ares, L., Horn, L., et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N. Engl. J. Med. 373 (2015), 1627–1639.
2. Brahmer, J., Reckamp, K.L., Baas, P., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373 (2015), 123–135.
3. Reck, M., Rodríguez-Abreu, D., Robinson, A.G., et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375 (2016), 1823–1833.
4. Weber, F.S., et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J. Clin. Oncol. 35 (2017), 785–792.
5. Sanlorenzo, M., Vujic, I., Daud, A., et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 151 (2015), 1206–1212.
6. Teulings, H.E., Limpens, J., Jansen, S.N., et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J. Clin. Oncol. 33 (2015), 773–781.
7. Haratani, K., Hayashi, H., Chiba, Y., et al. Association of immune-Related adverse events with nivolumab efficacy in non-Small-Cell lung cancer. JAMA Oncol., 2017 (epub ahead of print).
8. Teraoka, S., Fujimoto, D., Morimoto, T., et al. Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: a prospective cohort study. J. Thorac. Oncol. 12 (2017), 1798–1805.